# Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

> **NCT01438073** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 96 (actual)

## Conditions studied

- Hypogonadotropic Hypogonadism
- Healthy Postmenopausal Women
- Agonadism

## Interventions

- **DRUG:** kisspeptin 112-121
- **DRUG:** GnRH

## Key facts

- **NCT ID:** NCT01438073
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2022-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01438073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01438073, "Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01438073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*